The global impact of SARS-CoV-2 in 181 people with cystic fibrosis.
J Cyst Fibros
; 19(6): 868-871, 2020 11.
Article
in English
| MEDLINE | ID: covidwho-907134
ABSTRACT
With the growing SARS-CoV-2 pandemic, we need to better understand its impact in specific patient groups like those with Cystic Fibrosis (CF). We report on 181 people with CF (32 post-transplant) from 19 countries diagnosed with SARS-CoV-2 prior to 13 June 2020. Infection with SARS-CoV-2 appears to exhibit a similar spectrum of outcomes to that seen in the general population, with 11 people admitted to intensive care (7 post-transplant), and 7 deaths (3 post-transplant). A more severe clinical course may be associated with older age, CF-related diabetes, lower lung function in the year prior to infection, and having received an organ transplant. Whilst outcomes in this large cohort are better than initially feared overall, possibly due to a protective effect of the relatively younger age of the CF population compared to other chronic conditions, SARS-CoV-2 is not a benign disease for all people in this patient group.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Lung Transplantation
/
Cystic Fibrosis
/
SARS-CoV-2
/
COVID-19
/
Hospitalization
Type of study:
Cohort study
/
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
English
Journal:
J Cyst Fibros
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS